Stevanato Group S.p.A., a global provider of drug containment, delivery, and diagnostic solutions, reported an 8% increase in revenue for the second quarter of 2025, reaching €280.0 million. This growth was primarily driven by a 10% increase in the Biopharmaceutical and Diagnostic Solutions segment, which offset a 2% decline in the Engineering Segment. High-value solutions contributed to €116.8 million of total revenue, representing 42% of the quarter's revenue, bolstered by strong demand for high-value syringes and EZ-fill® products. The company also reported a gross profit margin increase of 210 basis points to 28.1% and an adjusted EBITDA margin increase of 240 basis points to 23.2%. Diluted earnings per share and adjusted diluted earnings per share were both reported at €0.11. Stevanato Group is maintaining its fiscal 2025 guidance, expecting revenue between €1.160 billion and €1.190 billion, adjusted EBITDA from €288.5 million to €301.8 million, and adjusted diluted EPS ranging from €0.50 to €0.54. The company believes it has adequate liquidity to support its strategic priorities over the next twelve months.